Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality.v
